Integrated network pharmacology, RNA sequencing, and experimental validation studies have revealed that CE inhibits cholesterol synthesis in SCLC cells by downregulating key enzymes, including HMGCR, HMGCS1, IDI1, FDFT1, and SQLE [43]. This evidence concerns the gene IDI1 and small cell lung carcinoma.